Statistik Asas
| CIK | 1846253 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OmniAb, Inc. - Equity Warrant
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 25, 2025 |
OMNIAB, INC. SECURITIES PURCHASE AGREEMENT EX-10.1 Exhibit 10.1 OMNIAB, INC. SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of August 24, 2025 (the “Effective Date”), by and between OMNIAB, INC., a Delaware corporation (the “Company”), and each of the purchasers whose names are set forth on Schedule A hereto (each, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Purchasers des |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2025 OMNIAB, INC. (Exact name of registrant as specified in its charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 25, 2025 |
OmniAb Announces $30 Million Private Placement EX-99.1 Exhibit 99.1 OmniAb Announces $30 Million Private Placement EMERYVILLE, Calif. (August 25, 2025) – OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commis |
|
| August 6, 2025 |
Exhibit 99.1 OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (August 6, 2025) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. “Our business is performing very well as w |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-40720 OMNIAB, INC. (Exac |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2025 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 8, 2025 |
Exhibit 99.1 OmniAb Reports First Quarter 2025 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (May 8, 2025) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. “We have started the year with robust deal flow, incl |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2025 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-40720 OMNIAB, INC. (Exa |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2025 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 18, 2025 |
As filed with the Securities and Exchange Commission on March 18, 2025 As filed with the Securities and Exchange Commission on March 18, 2025 Registration No. |
|
| March 18, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 18, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) OmniAb, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.00 |
|
| March 18, 2025 |
Exhibit 19 OmniAb, Inc. Insider Trading Compliance Policy and Procedures (as amended and restated effective March 28, 2023) Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this info |
|
| March 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-40720 OMNIAB, INC. (Exact name of |
|
| March 18, 2025 |
Exhibit 99.1 OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (March 18, 2025) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. “2024 was a remarkable ye |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-40720 OMNIAB, INC. |
|
| November 12, 2024 |
Exhibit 99.1 OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (November 12, 2024) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. “We are pleased to report another |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Com |
|
| September 24, 2024 |
5980 Horton Street Suite 600 Emeryville, CA 94608 September 24, 2024 VIA EDGAR Jeanne Baker Al Pavot Office of Industrial Applications and Services Division of Corporation Finance U. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commis |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-40720 OMNIAB, INC. (Exac |
|
| August 8, 2024 |
Exhibit 99.1 OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (August 8, 2024) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. “Second quarter results were in-line with |
|
| July 2, 2024 |
EX-99.1 2 tm2418750d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 13d-1(k)(1) thereunder, the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13(d) of the Exchange Act or any rule or regulation the |
|
| July 2, 2024 |
OABI / OmniAb, Inc. / Avista Capital Managing Member V, LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2418750d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* OmniAb, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 68218J103 (CUSIP Number) Avista Capital Partners 65 East 55th Street, 18th Floor New York, NY 10 |
|
| July 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 OMNIAB, INC. (Exact name of registrant as specified in its charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 OMNIAB, INC. (Exact name of registrant as specified in its charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-40720 OMNIAB, INC. (Exa |
|
| May 9, 2024 |
Exhibit 99.1 OmniAb Reports First Quarter 2024 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (May 9, 2024) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. “The OmniAb team continued to make great progress thi |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commissio |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by |
|
| March 25, 2024 |
OMNIAB, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Exhibit 97 OMNIAB, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION OmniAb, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Policy This Policy shall a |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-40720 OMNIAB, INC. (Exact name of |
|
| March 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 20, 2024 |
Exhibit 99.1 OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (March 20, 2024) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. “2023 was a year of signi |
|
| December 14, 2023 |
OmniAb, Inc. 5980 Horton Street, Suite 600 Emeryville, California 94608 OmniAb, Inc. 5980 Horton Street, Suite 600 Emeryville, California 94608 December 14, 2023 VIA EDGAR Margaret Schwartz Office of Industrial Applications and Services Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: OmniAb, Inc. Registration Statement on Form S-3 File No. 333-275966 To the addressee set forth above: Pursuant to Rul |
|
| December 8, 2023 |
Exhibit 4.7 OMNIAB, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establishment of Ter |
|
| December 8, 2023 |
Open Market Sale AgreementSM, dated December 8, 2023, between the Company and Jefferies LLC Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM December 8, 2023 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: OmniAb, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par |
|
| December 8, 2023 |
As filed with the Securities and Exchange Commission on December 8, 2023 Table of Contents As filed with the Securities and Exchange Commission on December 8, 2023 Registration No. |
|
| December 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) OmniAb, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Regi |
|
| December 8, 2023 |
As filed with the Securities and Exchange Commission on December 8, 2023 Table of Contents As filed with the Securities and Exchange Commission on December 8, 2023 Registration No. |
|
| November 13, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268613 Prospectus Supplement No. 4 (To Prospectus dated February 10, 2023) OmniAb, Inc. This prospectus supplement updates, amends and supplements the prospectus dated February 10, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-268613). Capitalized terms used in this prospectus supple |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-40720 OMNIAB, INC. |
|
| November 9, 2023 |
Exhibit 99.1 OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights Webcast including Research & Technology Event begins at 11:00 a.m. Eastern time today EMERYVILLE, Calif. (November 9, 2023) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates. “Our business mo |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Comm |
|
| November 2, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268613 Prospectus Supplement No. 3 (To Prospectus dated February 10, 2023) OmniAb, Inc. This prospectus supplement updates, amends and supplements the prospectus dated February 10, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-268613). Capitalized terms used in this prospectus supple |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Comm |
|
| August 10, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268613 Prospectus Supplement No. 2 (To Prospectus dated February 10, 2023) OmniAb, Inc. This prospectus supplement updates, amends and supplements the prospectus dated February 10, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-268613). Capitalized terms used in this prospectus supple |
|
| August 10, 2023 |
Exhibit 99.1 OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (August 10, 2023) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates. “Our business continued to grow and perfo |
|
| August 10, 2023 |
Exhibit 10.1 OMNIAB, INC. DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (as amended and restated effective June 1, 2023) I. DIRECTOR COMPENSATION Non-employee members of the board of directors (the “Board”) of OmniAb, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Director Compensation Policy. The cash compensation and stock awards described |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commi |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-40720 OMNIAB, INC. (Exac |
|
| June 26, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commiss |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Period From to . Commission File Number: 001-40720 OMNIAB, INC. (Exa |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commissi |
|
| May 11, 2023 |
Exhibit 99.1 OmniAb Reports First Quarter 2023 Financial Results and Business Highlights Conference Call with Slides Begins at 8:30 a.m. Eastern Time Today EMERYVILLE, Calif. (May 11, 2023) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates. “Our first quarter performance is a strong start to |
|
| May 5, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on May 5, 2023 Registration No. |
|
| May 5, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OmniAb, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees Pr |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by |
|
| May 1, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 POS EX 1 post-effectiveamendmentno1.htm POS EX As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. 333-268613 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OMNIAB, INC. (Exact name of registrant as specified in its charter) Delaware 8731 9 |
|
| March 31, 2023 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-268613 Prospectus Supplement No. 1 (To Prospectus dated February 10, 2023) OmniAb, Inc. This prospectus supplement updates, amends and supplements the prospectus dated February 10, 2023 (the “Prospectus”), which forms a part of our Registration Statement on Form S-1 (Registration No. 333-268613). Capitalized terms used in this prospectus supple |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 OMNIAB, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation or organization) (Commis |
|
| March 30, 2023 |
Exhibit 99.1 OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. (March 30, 2023) – OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates. “Following the closing of |
|
| March 30, 2023 |
Exhibit 10.26 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. ASSIGNMENT OF LEASE, CONSENT TO ASSIGNMENT OF LEASE AND FIRST AMENDMENT TO LEASE This Assignment of Lease, Consent to Assignment of Lease and First Amendment |
|
| March 30, 2023 |
Exhibit 4.5 DESCRIPTION OF OUR SECURITIES The following is a description of the capital stock of OmniAb, Inc. (“we,” “us,” and “our”) and certain provisions of our certificate of incorporation and bylaws and the General Corporation Law of the State of Delaware (the “DGCL”), as well as the terms of our Warrants (as defined below). This description is summarized from, and qualified in its entirety b |
|
| March 30, 2023 |
Certificate of Incorporation of the Registrant Exhibit 3.1 CERTIFICATE OF INCORPORATION OF OMNIAB, INC. ARTICLE I NAME The name of the corporation is OmniAb, Inc. (the “Corporation”). ARTICLE II REGISTERED OFFICE AND AGENT The address of the Corporation’s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808, and the name of its registered agent |
|
| March 30, 2023 |
Exhibit 10.19 OMNIAB, INC. DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY (as amended and restated effective February 3, 2023) I. DIRECTOR COMPENSATION Non-employee members of the board of directors (the “Board”) of OmniAb, Inc. (the “Company”) shall be eligible to receive cash and equity compensation as set forth in this Director Compensation Policy. The cash compensation and stock awards descr |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-40720 OMNIAB, INC. (Exact name of |
|
| March 30, 2023 |
Exhibit 10.21 CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (“Agreement”) is made effective as of November 1, 2022, by and between OmniAb, Inc., a Delaware corporation (the “Company”), and Matthew W. Foehr (“Employee”). The parties agree as follows: 1. Definitions. For purposes of this Agreement, the following terms shall have the following meanings: (a) “Cause” |
|
| March 30, 2023 |
Exhibit 10.23 CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (“Agreement”) is made effective as of November 1, 2022, by and between OmniAb, Inc., a Delaware corporation (the “Company”), and Charles S. Berkman (“Employee”). The parties agree as follows: 1. Definitions. For purposes of this Agreement, the following terms shall have the following meanings: (a) “Cause |
|
| March 30, 2023 |
Exhibit 10.22 CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (“Agreement”) is made effective as of November 1, 2022, by and between OmniAb, Inc., a Delaware corporation (the “Company”), and Kurt A. Gustafson (“Employee”). The parties agree as follows: 1. Definitions. For purposes of this Agreement, the following terms shall have the following meanings: (a) “Cause” |
|
| February 14, 2023 |
OABI / OmniAb Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* OmniAb, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 68218J103 (CUSIP Numb |
|
| February 13, 2023 |
OABI / OmniAb Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment SC 13G/A 1 OABISC13GA2023.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) OMNIAB, INC. (formerly Avista Public Acquisition Corp. II) (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 68218J103 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires fil |
|
| February 10, 2023 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-268613 PROSPECTUS OmniAb, Inc. Up to 36,450,645 Shares of Common Stock Up to 11,345,489 Warrants Up to 19,012,156 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the issuance by OmniAb, Inc. (“we,” “us,” “our,” the “Company,” “Registrant,” and “OmniAb”) of up to 24,273,938 shares of c |
|
| February 10, 2023 |
OABI / OmniAb Inc / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* OmniAb, Inc. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 68218J103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| February 8, 2023 |
OmniAb, Inc. 5980 Horton Street, Suite 600 Emeryville, California 94608 February 8, 2023 OmniAb, Inc. 5980 Horton Street, Suite 600 Emeryville, California 94608 February 8, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Nicholas Nalbantian Re: OmniAb, Inc. Registration Statement on Form S-1 (As Amended) File No. 333-268613 Ladies and Gentlemen: In accor |
|
| February 7, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OmniAb, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to |
|
| February 7, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on February 6, 2023 Registration No. |
|
| February 6, 2023 |
CORRESP 1 filename1.htm 12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los Angeles T |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 OmniAb, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| January 9, 2023 |
EX-99.1 2 d428015dex991.htm EX-99.1 OmniAb, Inc. Nasdaq: OABI January 2023 Exhibit 99.1 We caution you that this presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, expected cash runway, business strategy, our expectations re |
|
| January 5, 2023 |
CORRESP 1 filename1.htm 12670 High Bluff Drive San Diego, California 92130 Tel: +1.858.523.5400 Fax: +1.858.523.5450 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul January 5, 2023 Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Av |
|
| January 5, 2023 |
Table of Contents As filed with the Securities and Exchange Commission on January 5, 2023 Registration No. |
|
| January 3, 2023 |
Power of Attorney (see signature page) S-8 As filed with the Securities and Exchange Commission on January 3, 2023 Registration No. |
|
| January 3, 2023 |
Calculation of Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) OmniAb, Inc. (Exact name of registrant as specified in its charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.00 |
|
| December 13, 2022 |
Exhibit 99.1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 13d-1(k)(1) thereunder, the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13(d) of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement |
|
| December 13, 2022 |
OABI / OmniAb Inc / Avista Acquisition LP II - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 30, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on November 30, 2022 Registration No. |
|
| November 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) OmniAb, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2022 OmniAb, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-40720 (Commission File Number) 98-158 |
|
| November 15, 2022 |
OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights Exhibit 99.1 OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights EMERYVILLE, Calif. (November 15, 2022) ? OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) until its spin-off as an independent publicly |
|
| November 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2022 OmniAb, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 14, 2022 |
OMNIAB MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.1 Exhibit 99.1 OMNIAB MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Unless the context otherwise requires, references in this Management’s Discussion and Analysis of Financial Condition and Results of Operations to “OmniAb,” “we,” “us” and “our” refer to OmniAb, Inc., a Delaware corporation (which changed its name to OmniAb Operations, Inc. on October |
|
| November 14, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below and not otherwise defined in this Exhibit 99.1 have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 7, 2022. Unless the context otherwise requires, the “Company” refers to OmniAb, Inc. |
|
| November 14, 2022 |
Exhibit 99.1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 13d-1(k)(1) thereunder, the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13(d) of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 2 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 OmniAb, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation) (Co |
|
| November 14, 2022 |
OABI / OmniAb Inc / Avista Acquisition LP II - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| November 14, 2022 |
EX-99.2 Exhibit 99.2 OmniAb, Inc. (which changed its name to OmniAb Operations, Inc. on October 31, 2022) (A Business of Ligand Pharmaceuticals Incorporated) CONDENSED COMBINED BALANCE SHEETS (in thousands) September 30, 2022 December 31, 2021 (Unaudited) ASSETS Current assets: Accounts receivable, net $ 4,722 $ 21,136 Prepaid expenses 1,125 785 Transaction costs 5,931 — Other current assets 1,237 |
|
| November 10, 2022 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2022 |
Letter from Marcum LLP to the SEC. Exhibit 16.1 November 7, 2022 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by OmniAb, Inc. (formerly known as Avista Public Acquisition Corp. II) under Item 4.01 of its Form 8-K dated November 7, 2022. We agree with the statements concerning our Firm in such Form 8-K; we are not in a positi |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 OmniAb, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| November 7, 2022 |
OmniAb, Inc. 2022 Ligand Service Provider Assumed Award Plan. Exhibit 10.18 OMNIAB, INC. 2022 LIGAND SERVICE PROVIDER ASSUMED AWARD PLAN ARTICLE ONE GENERAL PROVISIONS I. PURPOSE OF THE PLAN The Corporation is a party to the transactions contemplated by that certain Separation and Distribution Agreement, dated as of March 23, 2022, by and among Ligand, the Corporation, Avista Public Acquisition Corp. II (?Merger Parent?), and Orwell Merger Sub Inc. (collecti |
|
| November 7, 2022 |
Certificate of Incorporation of the Registrant. Exhibit 3.1 CERTIFICATE OF INCORPORATION OF OMNIAB, INC. ARTICLE I NAME The name of the corporation is OmniAb, Inc. (the ?Corporation?). ARTICLE II REGISTERED OFFICE AND AGENT The address of the Corporation?s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808, and the name of its registered agent |
|
| November 7, 2022 |
Exhibit 10.21 OMNIAB, INC. SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Effective Date: November 1, 2022 1. Purpose. The purpose of this OmniAb, Inc. Severance Plan (this ?Plan?) is to provide certain Severance Payments and Benefits (as defined below) to designated employees of the Company in the event of a termination of their employment in certain specified circumstances. This Plan is an ?employe |
|
| November 7, 2022 |
Exhibit 4.2 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT THIS ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT (the ?Agreement?) is entered into and effective as of November 1, 2022 by and among OmniAb, Inc., a Delaware corporation (the ?Company?), Continental Stock Transfer & Trust Company, a New York corporation (?Continental?) and Computershare Trust Company, N.A., a federally chartered trust c |
|
| November 7, 2022 |
Exhibit 10.19 OMNIAB, INC. 2022 OMNIAB SERVICE PROVIDER ASSUMED AWARD PLAN ARTICLE ONE GENERAL PROVISIONS I. PURPOSE OF THE PLAN The Corporation is a party to the transactions contemplated by that certain Separation and Distribution Agreement, dated as of March 23, 2022, by and among Ligand, the Corporation, Avista Public Acquisition Corp. II (?Merger Parent?), and Orwell Merger Sub Inc. (collecti |
|
| November 7, 2022 |
Exhibit 10.11 TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this ?Agreement?), effective as of the Distribution Time of the Separation and Distribution Agreement (as defined below) (the ?Effective Date?), by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (?Ligand? or ?Provider?), and OmniAb Operations, Inc., a Delaware Corporation (?OmniAb?). Each of Pr |
|
| November 7, 2022 |
Exhibit 10.11 TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this ?Agreement?), effective as of the Distribution Time of the Separation and Distribution Agreement (as defined below) (the ?Effective Date?), by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (?Ligand? or ?Provider?), and OmniAb Operations, Inc., a Delaware Corporation (?OmniAb?). Each of Pr |
|
| November 7, 2022 |
OmniAb, Inc. 2022 OmniAb Service Provider Assumed Award Plan. Exhibit 10.19 OMNIAB, INC. 2022 OMNIAB SERVICE PROVIDER ASSUMED AWARD PLAN ARTICLE ONE GENERAL PROVISIONS I. PURPOSE OF THE PLAN The Corporation is a party to the transactions contemplated by that certain Separation and Distribution Agreement, dated as of March 23, 2022, by and among Ligand, the Corporation, Avista Public Acquisition Corp. II (?Merger Parent?), and Orwell Merger Sub Inc. (collecti |
|
| November 7, 2022 |
Exhibit 4.2 ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT THIS ASSIGNMENT, ASSUMPTION AND AMENDMENT AGREEMENT (the ?Agreement?) is entered into and effective as of November 1, 2022 by and among OmniAb, Inc., a Delaware corporation (the ?Company?), Continental Stock Transfer & Trust Company, a New York corporation (?Continental?) and Computershare Trust Company, N.A., a federally chartered trust c |
|
| November 7, 2022 |
Exhibit 21.1 List of Subsidiaries of the Registrant Wholly Owned Subsidiary Place of Incorporation Ab Initio Biotherapeutics, Inc. Delaware Crystal Bioscience, Inc. California Icagen, LLC Delaware OmniAb Operations, Inc. Delaware Taurus Biosciences, LLC Delaware xCella Biosciences, Inc. Delaware |
|
| November 7, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below and not otherwise defined in this Exhibit 99.1 have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 7, 2022. Unless the context otherwise requires, the ?Company? refers to OmniAb, Inc., a Dela |
|
| November 7, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below and not otherwise defined in this Exhibit 99.1 have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 7, 2022. Unless the context otherwise requires, the ?Company? refers to OmniAb, Inc., a Dela |
|
| November 7, 2022 |
List of Subsidiaries of OmniAb, Inc. Exhibit 21.1 List of Subsidiaries of the Registrant Wholly Owned Subsidiary Place of Incorporation Ab Initio Biotherapeutics, Inc. Delaware Crystal Bioscience, Inc. California Icagen, LLC Delaware OmniAb Operations, Inc. Delaware Taurus Biosciences, LLC Delaware xCella Biosciences, Inc. Delaware |
|
| November 7, 2022 |
Exhibit 16.1 November 7, 2022 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Commissioners: We have read the statements made by OmniAb, Inc. (formerly known as Avista Public Acquisition Corp. II) under Item 4.01 of its Form 8-K dated November 7, 2022. We agree with the statements concerning our Firm in such Form 8-K; we are not in a positi |
|
| November 7, 2022 |
Exhibit 10.7 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this ?Agreement?), dated as of Novembe |
|
| November 7, 2022 |
OmniAb, Inc. Director Compensation and Stock Ownership Policy Exhibit 10.20 OMNIAB, INC. DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY I. DIRECTOR COMPENSATION Non-employee members of the board of directors (the ?Board?) of OmniAb, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Director Compensation Policy, effective as of the date of the consummation of the transactions (the ?Merger?) contemplated by t |
|
| November 7, 2022 |
Exhibit 10.15 OMNIAB, INC. 2022 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2022 Incentive Award Plan (as amended from time to time, the ?Plan?) of OmniAb, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Part |
|
| November 7, 2022 |
Exhibit 10.14 OMNIAB, INC. 2022 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2022 Incentive Award Plan (as amended from time to time, the ?Plan?) of OmniAb, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Participant?) the stoc |
|
| November 7, 2022 |
Form of Stock Option Agreement under the OmniAb, Inc. 2022 Incentive Award Plan. Exhibit 10.14 OMNIAB, INC. 2022 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2022 Incentive Award Plan (as amended from time to time, the ?Plan?) of OmniAb, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Participant?) the stoc |
|
| November 7, 2022 |
Exhibit 3.1 CERTIFICATE OF INCORPORATION OF OMNIAB, INC. ARTICLE I NAME The name of the corporation is OmniAb, Inc. (the ?Corporation?). ARTICLE II REGISTERED OFFICE AND AGENT The address of the Corporation?s registered office in the State of Delaware is Corporation Service Company, 251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808, and the name of its registered agent |
|
| November 7, 2022 |
EX-3.2 Exhibit 3.2 Bylaws of OmniAb, Inc. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I — CORPORATE OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE II — MEETINGS OF STOCKHOLDERS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meeting 1 Section 2.3 Special Meeting 1 Section 2.4 Notice of Business to be Brought before a Meeting 1 Section 2.5 Notice of N |
|
| November 7, 2022 |
Exhibit 10.7 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this ?Agreement?), dated as of Novembe |
|
| November 7, 2022 |
Exhibit 10.21 OMNIAB, INC. SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION Effective Date: November 1, 2022 1. Purpose. The purpose of this OmniAb, Inc. Severance Plan (this ?Plan?) is to provide certain Severance Payments and Benefits (as defined below) to designated employees of the Company in the event of a termination of their employment in certain specified circumstances. This Plan is an ?employe |
|
| November 7, 2022 |
Form of Restricted Stock Unit Agreement under the OmniAb, Inc. 2022 Incentive Award Plan. Exhibit 10.15 OMNIAB, INC. 2022 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2022 Incentive Award Plan (as amended from time to time, the ?Plan?) of OmniAb, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Part |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 OmniAb, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40720 98-1584818 (State or other jurisdiction of incorporation) ( |
|
| November 7, 2022 |
Exhibit 3.2 Bylaws of OmniAb, Inc. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I ? CORPORATE OFFICES 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE II ? MEETINGS OF STOCKHOLDERS 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meeting 1 Section 2.3 Special Meeting 1 Section 2.4 Notice of Business to be Brought before a Meeting 1 Section 2.5 Notice of Nominati |
|
| November 7, 2022 |
Exhibit 10.12 TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this ?Agreement?), effective as of the Distribution Time of the Separation and Distribution Agreement (as defined below) (the ?Effective Date?), by and between OmniAb Operations, Inc., a Delaware corporation (?OmniAb? or ?Provider?), and Ligand Pharmaceuticals Incorporated, a Delaware Corporation (?Ligand?). Each of Pr |
|
| November 7, 2022 |
Exhibit 10.18 OMNIAB, INC. 2022 LIGAND SERVICE PROVIDER ASSUMED AWARD PLAN ARTICLE ONE GENERAL PROVISIONS I. PURPOSE OF THE PLAN The Corporation is a party to the transactions contemplated by that certain Separation and Distribution Agreement, dated as of March 23, 2022, by and among Ligand, the Corporation, Avista Public Acquisition Corp. II (?Merger Parent?), and Orwell Merger Sub Inc. (collecti |
|
| November 7, 2022 |
Exhibit 10.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. TAX MATTERS AGREEMENT by and among OMNIAB, INC. (F/K/A AVISTA PUBLIC ACQUISITION CORP. II) LIGAND PHARMACEUTICALS INCORPORATED and OMNIAB OPERATIONS, INC. (F/K/A OMNIAB, INC.) D |
|
| November 7, 2022 |
Form of Performance Stock Unit Agreement under the OmniAb, Inc. 2022 Incentive Award Plan Exhibit 10.16 OMNIAB, INC. 2022 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2022 Incentive Award Plan (as amended from time to time, the ?Plan?) of OmniAb, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Part |
|
| November 7, 2022 |
Form of Performance Stock Unit Agreement under the OmniAb, Inc. 2022 Incentive Award Plan. Exhibit 10.16 OMNIAB, INC. 2022 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2022 Incentive Award Plan (as amended from time to time, the ?Plan?) of OmniAb, Inc. (the ?Company?). The Company hereby grants to the participant listed below (?Part |
|
| November 7, 2022 |
Exhibit 10.20 OMNIAB, INC. DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY I. DIRECTOR COMPENSATION Non-employee members of the board of directors (the ?Board?) of OmniAb, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Director Compensation Policy, effective as of the date of the consummation of the transactions (the ?Merger?) contemplated by t |
|
| November 7, 2022 |
Exhibit 10.12 TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this ?Agreement?), effective as of the Distribution Time of the Separation and Distribution Agreement (as defined below) (the ?Effective Date?), by and between OmniAb Operations, Inc., a Delaware corporation (?OmniAb? or ?Provider?), and Ligand Pharmaceuticals Incorporated, a Delaware Corporation (?Ligand?). Each of Pr |
|
| November 7, 2022 |
Exhibit 10.10 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. TAX MATTERS AGREEMENT by and among OMNIAB, INC. (F/K/A AVISTA PUBLIC ACQUISITION CORP. II) LIGAND PHARMACEUTICALS INCORPORATED and OMNIAB OPERATIONS, INC. (F/K/A OMNIAB, INC.) D |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commiss |
|
| October 24, 2022 |
OmniAb, Inc. 2022 Incentive Award Plan Exhibit 10.1 OMNIAB, INC. 2022 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Capitalized terms used in the Plan are defin |
|
| October 24, 2022 |
Exhibit 10.2 OMNIAB, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purpose of this Plan is to assist Eligible Employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company. The Plan consists of two components: (i) the Section 423 Component and (ii) the Non-Section 423 Component. The Section 423 Component is intended to qualify as an |
|
| October 3, 2022 |
Filed by Avista Public Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Avista Public Acquisition Corp. II Commission File No. 001-40720 Date: October 3, 2022 Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinar |
|
| October 3, 2022 |
Filed by Avista Public Acquisition Corp. II Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Avista Public Acquisition Corp. II Commission File No. 001-40720 Date: October 3, 2022 How to vote? Please follow the instructions provided on the enclosed proxy card or vote instruction form. How do I |
|
| September 30, 2022 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)3? ?Registration No. 333-264525? AVISTA PUBLIC ACQUISITION CORP. II A Cayman Islands Exempted Company (Company Number 306402) 65 East 55th Street, 18th Floor New York, NY 10022 PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF AVISTA PUBLIC ACQUISITION CORP. II (A CAYMAN ISLANDS EXEMPTED COMPANY) PROSPECTUS FOR 149,137,552 SHARES OF COMMON STOCK A |
|
| September 28, 2022 |
[Remainder of Page Intentionally Left Blank] VIA EDGAR September 28, 2022 Avista Public Acquisition Corp. II 65 East 55th Street 18th Floor New York, NY 10022 (212) 593-6900 Brian Fetterolf and Erin Jaskot U.S. Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street, NE Washington, D.C. 20549-3561 Re: Avista Public Acquisition Corp. II Amendment No. 5 to Registration Statement on Form S-4 Fi |
|
| September 27, 2022 |
[Remainder of Page Intentionally Left Blank] 767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax September 27, 2022 VIA EDGAR TRANSMISSION Brian Fetterolf United States Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street NE Washington, D. |
|
| September 27, 2022 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 27, 2022 Registration No. |
|
| September 13, 2022 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 12, 2022 Registration No. |
|
| September 13, 2022 |
Form of Proxy Card for Avista Public Acquisition Corp. II’s extraordinary general meeting. Exhibit 99.1 AVISTA PUBLIC ACQUISITION CORP. II PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING ELECTRONICALLY. 20140 Avista Public Acquisition Corp. II Proxy Card REV1 Front INTERNET ? www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. Vote at the Meeting ? If you plan to attend |
|
| September 13, 2022 |
Exhibit 24.2 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned constitutes and appoints each of Benjamin Silbert and John Cafasso, each acting alone, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-4 (including all |
|
| September 13, 2022 |
Exhibit 10.26 OFFICE/LABORATORY LEASE BETWEEN EMERY STATION OFFICE II, LLC (LANDLORD) AND LIGAND PHARMACEUTICALS INCORPORATED (TENANT) 5980 Horton Street Emeryville, California Table of Contents Page Article 1 BASIC LEASE PROVISIONS 1 1.1 BASIC LEASE PROVISIONS 1 1.2 ENUMERATION OF EXHIBITS AND RIDER(S) 5 1.3 DEFINITIONS 5 Article 2 PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING 11 2.1 LE |
|
| September 12, 2022 |
[Remainder of Page Intentionally Left Blank] CORRESP 1 filename1.htm 767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax September 12, 2022 VIA EDGAR TRANSMISSION Brian Fetterolf United States Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street NE Washington, D.C. 20549 Re: Avista Public Acquisition Corp. II Amendment No. 3 to Registration Statement on Form S |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2022 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commissi |
|
| August 24, 2022 |
425 1 tm2224508d2425.htm 425 Filed by: Ligand Pharmaceuticals Incorporated Commission File No.: 001-33093 Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Avista Public Acquisition Corp. II (Commission File No.: 001-40720) Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Ref |
|
| August 22, 2022 |
Form of 2022 OmniAb Service Provider Assumed Award Plan. Exhibit 10.21 OMNIAB, INC. 2022 OMNIAB SERVICE PROVIDER ASSUMED AWARD PLAN ARTICLE ONE GENERAL PROVISIONS I. PURPOSE OF THE PLAN The Corporation is a party to the transactions contemplated by that certain Separation and Distribution Agreement, dated as of March 23, 2022, by and among Ligand, the Corporation, Avista Public Acquisition Corp. II (?Merger Parent?), and Orwell Merger Sub Inc. (collecti |
|
| August 22, 2022 |
[Remainder of Page Intentionally Left Blank] 767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax August 22, 2022 VIA EDGAR TRANSMISSION Brian Fetterolf United States Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street NE Washington, D. |
|
| August 22, 2022 |
EX-FILING FEES 6 ahpa-20220416xexfilingfees.htm EX-FILING FEES Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-4 (Form Type) Avista Public Acquisition Corp. II (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Off |
|
| August 22, 2022 |
As filed with the Securities and Exchange Commission on August 22, 2022 Table of Contents As filed with the Securities and Exchange Commission on August 22, 2022 Registration No. |
|
| August 22, 2022 |
Form of 2022 Ligand Service Provider Assumed Award Plan. Exhibit 10.20 ? OMNIAB, INC. ? 2022 LIGAND SERVICE PROVIDER ASSUMED AWARD PLAN ? ARTICLE ONE ? GENERAL PROVISIONS ? I. PURPOSE OF THE PLAN ? The Corporation is a party to the transactions contemplated by that certain Separation and Distribution Agreement, dated as of March 23, 2022, by and among Ligand, the Corporation, Avista Public Acquisition Corp. II (?Merger Parent?), and Orwell Merger Sub In |
|
| August 12, 2022 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 26, 2022 |
Consent of Joshua Tamaroff to be named as a director. Exhibit 99.8 Consent to be Named as a Director In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| July 26, 2022 |
Exhibit 10.27 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Amended and Restated License Agreement This Amended and Restated License Agreement (?Agreement?) is made on May 29, 2020 by and between F. Hoffmann-La Roche |
|
| July 26, 2022 |
As filed with the Securities and Exchange Commission on July 26, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 26, 2022 Registration No. |
|
| July 26, 2022 |
Exhibit 10.25 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. ANTIBODY LICENSE AGREEMENT This Antibody License Agreement (?Agreement?) is entered into effective December 20, 2012 (?Effective Date?) by Open Monoclonal Te |
|
| July 26, 2022 |
Exhibit 10.26 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN ICAGEN, INC. AND CYSTIC FIBROSIS FOUNDATION RESEARCH, DEVELOPMENT AND COMMERCIALIZATION |
|
| July 26, 2022 |
[Remainder of Page Intentionally Left Blank] CORRESP 1 filename1.htm 767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax July 26, 2022 VIA EDGAR TRANSMISSION Brian Fetterolf United States Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street NE Washington, D.C. 20549 Re: Avista Public Acquisition Corp. II Amendment No. 1 to Registration Statement on Form S-4 Fi |
|
| June 21, 2022 |
Analyst Teach - In June 21, 2022 11 am EDT Exhibit 99.1 Analyst Teach - In June 21, 2022 11 am EDT 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (OmniAb), a wholly owned subsidiary of Ligand |
|
| June 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2022 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commission |
|
| June 21, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 21, 2022 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commission |
|
| June 21, 2022 |
Analyst Teach - In June 21, 2022 11 am EDT Exhibit 99.1 Analyst Teach - In June 21, 2022 11 am EDT 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (OmniAb), a wholly owned subsidiary of Ligand |
|
| June 13, 2022 |
As filed with the Securities and Exchange Commission on June 10, 2022 Table of Contents As filed with the Securities and Exchange Commission on June 10, 2022 Registration No. |
|
| June 13, 2022 |
Form of OmniAb, Inc. Change in Control Severance Agreement for Executive Officers. ? Exhibit 10.21 CHANGE IN CONTROL SEVERANCE AGREEMENT This Change in Control Severance Agreement (?Agreement?) is made effective as of , 2022, by and between OmniAb, Inc., a Delaware corporation (the ?Company?), and (?Employee?). The parties agree as follows: 1.Definitions. For purposes of this Agreement, the following terms shall have the following meanings: (a)?Cause? shall mean any of the follo |
|
| June 13, 2022 |
Form of OmniAb, Inc. Severance Plan. ? Exhibit 10.22 ? OMNIAB, INC. ? SEVERANCE PLAN ? AND SUMMARY PLAN DESCRIPTION ? Effective Date: [], 2022 ? 1.Purpose. The purpose of this OmniAb, Inc. Severance Plan (this ?Plan?) is to provide certain Severance Payments and Benefits (as defined below) to designated employees of the Company in the event of a termination of their employment in certain specified circumstances. This Plan is an ?empl |
|
| June 13, 2022 |
Form of OmniAb, Inc. Non-Employee Director Compensation Program. Exhibit 10.20 OMNIAB, INC. DIRECTOR COMPENSATION AND STOCK OWNERSHIP POLICY I. DIRECTOR COMPENSATION Non-employee members of the board of directors (the ?Board?) of OmniAb, Inc. (the ?Company?) shall be eligible to receive cash and equity compensation as set forth in this Director Compensation Policy, effective as of the date of the consummation of the transactions (the ?Merger?) contemplated by t |
|
| June 13, 2022 |
Specimen Common Stock Certificate of OmniAb, Inc. Exhibit 4.5 NUMBER SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [ ] ? OMNIAB, INC. A DELAWARE CORPORATION COMMON STOCK This Certifies that is the owner of ? FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE EACH, OF OMNIAB, INC. (THE ?CORPORATION?) transferable on the books of the Corporation in person or by duly authorized attorney upon surrender of this certif |
|
| June 10, 2022 |
[Remainder of Page Intentionally Left Blank] 767 Fifth Avenue New York, NY 10153-0119 +1 212 310 8000 tel +1 212 310 8007 fax June 10, 2022 VIA EDGAR TRANSMISSION Brian Fetterolf United States Securities and Exchange Commission Division of Corporation Finance Office of Trade & Services 100 F Street NE Washington, D. |
|
| May 20, 2022 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 16, 2022 |
Avista Public Acquisition Corp. II (Name of Registrant as Specified in Charter) UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Number: 3235-0058 Washington, D. |
|
| May 5, 2022 |
425 1 form425q12022earningsrele.htm 425 Filed by: Ligand Pharmaceuticals Incorporated Commission File No.: 001-33093 Pursuant to Rule 425 under the Securities Act of 1933 Subject Company: Avista Public Acquisition Corp. II (Commission File No.: 001-40720) Contacts: Ligand Pharmaceuticals Incorporated LHA Investor Relations Simon Latimer Bruce Voss Email: [email protected] Email: [email protected] |
|
| April 29, 2022 |
Avista Public Acquisition Corp. II 65 East 55th Street, 18th Floor New York, NY 10022 DEL AM 1 tm2212114d5delam.htm DEL AM Avista Public Acquisition Corp. II 65 East 55th Street, 18th Floor New York, NY 10022 April 29, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Delaying Amendment for Avista Public Acquisition Corp. II Registration Statement on Form S-4 (File No. 333-264525) Ladies and G |
|
| April 28, 2022 |
Power of Attorney (included on signature page to the initial filing of the Registration Statement). Table of Contents As filed with the Securities and Exchange Commission on April 27, 2022 Registration No. |
|
| April 28, 2022 |
Form of OmniAb, Inc. Indemnification Agreement for Directors and Officers. Exhibit 10.23 ? OMNIAB, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of , 20 by and between OmniAb, Inc., a Delaware corporation (the ?Company?), and , [a member of the Board of Directors/ an officer] of the Company (?Indemnitee?). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering indemnifica |
|
| April 28, 2022 |
? Exhibit 10.24 LAB LEASE BETWEEN EMERY STATION OFFICE II, LLC (LANDLORD) AND CRYSTAL BIOSCIENCE, INC. (TENANT) EMERY STATION NORTH Emeryville, California ? ARTICLE 1 BASIC LEASE PROVISIONS 1 1.1 BASIC LEASE PROVISIONS 1 1.2 ENUMERATION OF EXHIBITS AND RIDER 2 1.3 DEFINITIONS 3 ARTICLE 2 PREMISES, TERM, FAILURE TO GIVE POSSESSION, AND PARKING 8 2.1 LEASE OF PREMISES 8 2.2 TERM 9 2.3 FAILURE TO GIV |
|
| April 28, 2022 |
Antibody License Agreement between CNA Development LLC and OmniAb, Inc., dated December 20, 2012. ? Exhibit 10.25 ANTIBODY LICENSE AGREEMENT This Antibody License Agreement (?Agreement?) is entered into effective December 20, 2012 (?Effective Date?) by Open Monoclonal Technologies, Inc. (?OMT?), a Delaware corporation having its principal place of business at 2747 Ross Road, Suite A, Palo Alto, CA 94303 and CNA Development LLC (?Licensee?), a Delaware limited liability company, having its prin |
|
| April 28, 2022 |
Consent of Jennifer Cochran to be named as a director. Exhibit 99.4 Consent to be Named as a Director In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| April 28, 2022 |
Consent of Matthew W. Foehr to be named as a director. Exhibit 99.7 Consent to be Named as a Director In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| April 28, 2022 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables Form S-4 (Form Type) Avista Public Acquisition Corp. |
|
| April 28, 2022 |
? Exhibit 10.26 RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN ICAGEN, INC. AND CYSTIC FIBROSIS FOUNDATION ? ? ? RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT CONTENTS ? Clause Page ARTICLE I ? DEFINITIONS 1 ARTICLE II ? RESEARCH PLAN 6 ARTICLE III ? AWARD AMOUNT PAYMENTS; RECORDS 11 ARTICLE IV ? COMMERCIALIZATION; ROYALTIES 15 ARTICLE V ? CONFIDENTIALITY 18 ARTICLE V |
|
| April 28, 2022 |
Form of Proxy Card for Avista Public Acquisition Corp. II’s extraordinary general meeting. Exhibit 99.1 ? ? ? 20140 Avista Public Acquisition Corp. II Proxy Card REV1 Front YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet - QUICK ??? EASY IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Intern |
|
| April 28, 2022 |
? Exhibit 10.27 Amended and Restated License Agreement This Amended and Restated License Agreement (?Agreement?) is made on May 29, 2020 by and between F. Hoffmann-La Roche Ltd with an office and place of business at [***] (?Roche [***]?) and Hoffmann-La Roche lnc. with an office and place of business at [***] (?Roche US?; Roche [***] and Roche US together referred to as ?Roche?) on the one hand a |
|
| April 28, 2022 |
List of subsidiaries of OmniAb, Inc. ? Exhibit 21.1 List of Principal Subsidiaries of OmniAb, Inc. In connection with the separation of OmniAb, Inc. from Ligand Pharmaceuticals Incorporated, the following entities will become wholly owned subsidiaries of OmniAb, Inc. ? Wholly Owned Subsidiary Place of Incorporation ? ? ? Ab Initio Biotherapeutics, Inc. ? Delaware Crystal Bioscience, Inc. ? California Icagen, LLC ? Delaware Taurus Bio |
|
| April 28, 2022 |
Consent of Sunil Patel to be named as a director. EX-99.5 14 ahpa-20220416xex99d5.htm EXHIBIT-99.5 Exhibit 99.5 Consent to be Named as a Director In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in t |
|
| April 28, 2022 |
Consent of Carolyn Bertozzi to be named as a director. Exhibit 99.6 Consent to be Named as a Director In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| April 28, 2022 |
Consent of Sarah Boyce to be named as a director. Exhibit 99.3 Consent to be Named as a Director In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| April 28, 2022 |
Consent of John L. Higgins to be named as a director. Exhibit 99.2 Consent to be Named as a Director In connection with the filing by Avista Public Acquisition Corp. II of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 28, 2022 |
Exhibit 4.4 ? DESCRIPTION OF SECURITIES The following description sets forth certain material terms and provisions of the securities of Avista Public Acquisition Corp. II (?we,? ?us?, ?our? or the ?Company?) that are registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). References to our ?sponsor? refer to Avista Acquisition LP II, a Cayman Islands ex |
|
| March 24, 2022 |
? Exhibit 10.1 ? Execution Version ? EMPLOYEE MATTERS AGREEMENT ? This EMPLOYEE MATTERS AGREEMENT (this ?Agreement?), dated as of March?23, 2022, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (the ?Company?), OmniAb,?Inc., a Delaware corporation and a wholly owned subsidiary of the Company (?SpinCo?), Avista Public Acquisition Corp. II, a Cayman Islands e |
|
| March 24, 2022 |
Exhibit 2.2 Execution Version SEPARATION AND DISTRIBUTION AGREEMENT by and among LIGAND PHARMACEUTICALS INCORPORATED, OMNIAB, INC. and AVISTA PUBLIC ACQUISITION CORP. II Dated as of March 23, 2022 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATION 2 Section 1.1 General 2 Section 1.2 References; Interpretation 21 Article II THE SEPARATION 21 Section 2.1 General 21 Section 2.2 Restructu |
|
| March 24, 2022 |
Exhibit 2.3 Execution Version March 23, 2022 Avista Public Acquisition Corp. II 65 East 55th Street, 18th Floor New York, NY 10022 Re: Letter Agreement Ladies and Gentlemen: Reference is made to that certain Agreement and Plan of Merger, dated as of March 23, 2022 (the ?Merger Agreement?), by and among Ligand Pharmaceuticals Incorporated (?Ligand?), a Delaware corporation, OmniAb, Inc., a Delaware |
|
| March 24, 2022 |
? Exhibit 10.1 ? Execution Version ? EMPLOYEE MATTERS AGREEMENT ? This EMPLOYEE MATTERS AGREEMENT (this ?Agreement?), dated as of March?23, 2022, is entered into by and among Ligand Pharmaceuticals Incorporated, a Delaware corporation (the ?Company?), OmniAb,?Inc., a Delaware corporation and a wholly owned subsidiary of the Company (?SpinCo?), Avista Public Acquisition Corp. II, a Cayman Islands e |
|
| March 24, 2022 |
Exhibit 2.2 Execution Version SEPARATION AND DISTRIBUTION AGREEMENT by and among LIGAND PHARMACEUTICALS INCORPORATED, OMNIAB, INC. and AVISTA PUBLIC ACQUISITION CORP. II Dated as of March 23, 2022 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATION 2 Section 1.1 General 2 Section 1.2 References; Interpretation 21 Article II THE SEPARATION 21 Section 2.1 General 21 Section 2.2 Restructu |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2022 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commissio |
|
| March 24, 2022 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER DATED AS OF MARCH 23, 2022 by and among LIGAND PHARMACEUTICALS INCORPORATED, OMNIAB, INC., AVISTA PUBLIC ACQUISITION CORP. II and ORWELL MERGER SUB INC. -i- TABLE OF CONTENTS Page Article I DEFINITIONS 4 Section 1.1 Definitions 4 Section 1.2 Cross References 23 Section 1.3 Interpretation 24 Article II THE MERGER 26 Section 2.1 The Merger 2 |
|
| March 24, 2022 |
Exhibit 2.3 Execution Version March 23, 2022 Avista Public Acquisition Corp. II 65 East 55th Street, 18th Floor New York, NY 10022 Re: Letter Agreement Ladies and Gentlemen: Reference is made to that certain Agreement and Plan of Merger, dated as of March 23, 2022 (the ?Merger Agreement?), by and among Ligand Pharmaceuticals Incorporated (?Ligand?), a Delaware corporation, OmniAb, Inc., a Delaware |
|
| March 24, 2022 |
Exhibit 2.4 ? Execution Version ? AMENDED AND RESTATED FORWARD PURCHASE AGREEMENT ? This Amended and Restated Forward Purchase Agreement (this ?Agreement?) is entered into as of March?23, 2022, by and among Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), Avista Acquisition LP II, a Cayman Islands exempted limited partnership (the ?Purchaser?), and OmniAb,?Inc |
|
| March 24, 2022 |
Exhibit 2.4 ? Execution Version ? AMENDED AND RESTATED FORWARD PURCHASE AGREEMENT ? This Amended and Restated Forward Purchase Agreement (this ?Agreement?) is entered into as of March?23, 2022, by and among Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), Avista Acquisition LP II, a Cayman Islands exempted limited partnership (the ?Purchaser?), and OmniAb,?Inc |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2022 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commissio |
|
| March 24, 2022 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER DATED AS OF MARCH 23, 2022 by and among LIGAND PHARMACEUTICALS INCORPORATED, OMNIAB, INC., AVISTA PUBLIC ACQUISITION CORP. II and ORWELL MERGER SUB INC. -i- TABLE OF CONTENTS Page Article I DEFINITIONS 4 Section 1.1 Definitions 4 Section 1.2 Cross References 23 Section 1.3 Interpretation 24 Article II THE MERGER 26 Section 2.1 The Merger 2 |
|
| March 23, 2022 |
Exhibit 99.2 ANCHORED SPIN-OFF INVESTOR PRESENTATION March 2022 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (OmniAb), a wholly owned subsidiary o |
|
| March 23, 2022 |
Exhibit 99.1 Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Transaction will result in OmniAb becoming an independent publicly traded company Ligand?s shareholders to receive 100% of Ligand?s shares in OmniAb through a tax-free distribution immediately prior to the merger EMERYVILLE, CALIFORNIA and NEW YORK (March 23, 2022) ? Ligand Pharmaceuticals In |
|
| March 23, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2022 Avista Public Acquisition Corp. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commissio |
|
| March 23, 2022 |
Exhibit 99.3 Project Orwell Transcript Transcribed By: FINSIGHT 530 7th Avenue New York, NY 10018 DISCLAIMER: FINSIGHT makes every effort to ensure an accurate transcription. Enclosed is the output of transcribing from an audio recording. Although the transcription is largely accurate, in some cases, it may be incomplete or inaccurate due to inaudible passages or transcription errors. This transcr |
|
| March 23, 2022 |
Exhibit 99.2 ANCHORED SPIN-OFF INVESTOR PRESENTATION March 2022 2 LEGAL DISCLAIMERS About this Presentation This presentation is for informational purposes only to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Avista Public Acquisition Corp. II (APAC) and OmniAb, Inc. (OmniAb), a wholly owned subsidiary o |
|
| March 23, 2022 |
Exhibit 99.3 Project Orwell Transcript Transcribed By: FINSIGHT 530 7th Avenue New York, NY 10018 DISCLAIMER: FINSIGHT makes every effort to ensure an accurate transcription. Enclosed is the output of transcribing from an audio recording. Although the transcription is largely accurate, in some cases, it may be incomplete or inaccurate due to inaudible passages or transcription errors. This transcr |
|
| March 23, 2022 |
425 1 tm2210239d2425.htm 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2022 Avista Public Acquisition Corp. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or oth |
|
| March 23, 2022 |
Exhibit 99.1 Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II Transaction will result in OmniAb becoming an independent publicly traded company Ligand?s shareholders to receive 100% of Ligand?s shares in OmniAb through a tax-free distribution immediately prior to the merger EMERYVILLE, CALIFORNIA and NEW YORK (March 23, 2022) ? Ligand Pharmaceuticals In |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2022 Avista Public Acquisition Corp. II (Exact Name of Registrant as Specified in Charter) Cayman Islands 001-40720 95-1584818 (State or Other Jurisdiction of (Commission Fi |
|
| March 14, 2022 |
Exhibit 10.1 THIS PROMISSORY NOTE (this ?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE MAK |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Avista Public Acquisition Corp. II (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (the ?Shares?) (Title of Class of |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avista Public Acquisition Corp. II (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) G07247110 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 14, 2022 |
KYG072471025 / Avista Public Acquisition Corp. II / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avista Public Acquisition Corp. II (Name of Issuer) Class A Ordinary Shares, par value $0.0001 (Title of Class of Securities) G07247102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Avista Public Acquisition Corp. II (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Titles of Class of Securities) G07247102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) ? Rule 13d-l(b) ? R |
|
| February 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avista Public Acquisition Corp. II (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (Title of Class of Securities) G07247102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| January 28, 2022 |
AVISTA PUBLIC ACQUISITION CORP. II INDEX TO FINANCIAL STATEMENT Exhibit 99.1 AVISTA PUBLIC ACQUISITION CORP. II INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of August 12, 2021 (As Restated) F-3 Notes to Financial Statement (As Restated) F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Avista Public Acquisition Corp. II Opinion on the Financ |
|
| January 28, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2021 (August 12, 2021) AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (St |
|
| January 12, 2022 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2021 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commis |
|
| November 10, 2021 |
Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 27, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 27, 2021 AVISTA PUBLIC ACQUISITION CORP. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commi |
|
| September 27, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Avista Public Acquisition Corp. II Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing September 30, 2021 NEW YORK, NY, September 27, 2021 ? Avista Public Acquisition Corp. II (the ?Company?) announced that commencing September 30, 2021, holders of the units sold in the Company?s initial public offering of 23,000,000 units may e |
|
| September 23, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 23, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Class A ordinary shares of Avista Public Acquisition Corp. II, a Cayman Islands exempted company, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as am |
|
| August 23, 2021 |
CITADEL ADVISORS LLC - AVISTA PUBLIC ACQUISITION CORP. II UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Avista Public Acquisition Corp. II (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (Title of Class of Securities) G072 |
|
| August 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Avista Public Acquisition Corp. II (Name of Issuer) Class A Ordinary Shares, par value $0.0001 (Title of Class of Securities) G072471101 (CUSIP Number) August 10, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| August 18, 2021 |
AVISTA PUBLIC ACQUISITION CORP. II INDEX TO FINANCIAL STATEMENT Exhibit 99.1 AVISTA PUBLIC ACQUISITION CORP. II INDEX TO FINANCIAL STATEMENT Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of August 12, 2021 F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Avista Public Acquisition Corp. II Opinion on the Financial Statement We have audite |
|
| August 18, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2021 Avista Public Acquisition Corp. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of (Commissi |
|
| August 16, 2021 |
INTEGRATED CORE STRATEGIES (US) LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 AVISTA PUBLIC ACQUISITION CORP. II (Name of Issuer) CLASS A ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) G07247110** (CUSIP Number) AUGUST 10, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate |
|
| August 12, 2021 |
Exhibit 10.7 Execution Version FORWARD PURCHASE AGREEMENT This Forward Purchase Agreement (this ?Agreement?) is entered into as of August 9, 2021, by and between Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?) and Avista Acquisition LP II, a Cayman Islands exempted limited partnership (the ?Purchaser?). WHEREAS, the Company was incorporated for the purpose of |
|
| August 12, 2021 |
Exhibit 10.1 Execution Version INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this ?Agreement?) is made effective as of August 9, 2021 by and between Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), and Continental Stock Transfer & Trust Company, a New York corporation (the ?Trustee?). WHEREAS, the Company?s registration stat |
|
| August 12, 2021 |
Exhibit 99.1 Avista Public Acquisition Corp. II Announces Pricing of $200 Million Initial Public Offering August 9, 2021 NEW YORK, NY-(BUSINESS WIRE)-Avista Public Acquisition Corp. II (the ?Company?), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, announced today the pricing of its initial public offering of 20,000,000 unit |
|
| August 12, 2021 |
Exhibit 3.1 THE COMPANIES ACT (As Revised) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Avista Public Acquisition Corp. II (adopted by Special Resolution dated 9 AUGUST 2021 and effective on 9 AUGUST 2021) THE COMPANIES ACT (As Revised) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF |
|
| August 12, 2021 |
Exhibit 10.2 Execution Version REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND SHAREHOLDER RIGHTS AGREEMENT (this ?Agreement?), dated as of August 9, 2021, is made and entered into by and among Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), Avista Acquisition LP II, a Cayman Islands exempted limited partnership (the ?Sponsor?), and the un |
|
| August 12, 2021 |
Exhibit 10.4 Execution Version AVISTA PUBLIC ACQUISITION CORP. II 65 East 55th Street, 18th Floor New York, NY 10022 August 9, 2021 Avista Capital Holdings, LP 65 East 55th Street, 18th Floor New York, NY 10022 Ladies and Gentlemen: This letter will confirm our agreement that, commencing on the effective date (the ?Effective Date?) of the registration statement (the ?Registration Statement?) for t |
|
| August 12, 2021 |
Exhibit 10.5 Execution Version August 9, 2021 Avista Public Acquisition Corp. II 65 East 55th Street, 18th Floor New York, NY 10022 Re: Initial Public Offering Ladies and Gentlemen: This letter (this ?Letter Agreement?) is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) entered into by and between Avista Public Acquisition Corp. II, a Cayman Isla |
|
| August 12, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2021 Avista Public Acquisition Corp. II (Exact name of registrant as specified in its charter) Cayman Islands 001-40720 98-1584818 (State or other jurisdiction of incorporat |
|
| August 12, 2021 |
Exhibit 10.3 Execution Version PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (as it may from time to time be amended and including all exhibits referenced herein, this ?Agreement?), dated as of August 9, 2021, is entered into by and between Avista Public Acquisition Corp. II, a Cayman Islands exempted company (the ?Company?), and Avista Acquisitio |
